Covidien plc
Healthcare · Surgical & Medical Instruments & Apparatus · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.80B | $2.55B | $10.26B |
| Operating income | $1.99B | $2.13B | $2.08B | $2.04B | $2.06B | $1.81B |
| Net income | $441.0M | $439.0M | $1.91B | $1.87B | $1.63B | $907.0M |
| Total assets | $20.70B | $19.92B | $22.26B | $20.37B | $20.39B | $17.14B |
| Total liabilities | $10.58B | $10.68B | $11.69B | $10.56B | $11.41B | $9.14B |
| Equity | $10.06B | $9.24B | $10.56B | $9.82B | $8.97B | $8.00B |
| EPS (diluted) | $0.97 | $0.92 | $3.92 | $3.76 | $3.24 | $1.79 |
| Shares out. | 452.8M | 452.4M | 473.4M | 482.4M | 495.2M | 499.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- —
- Net margin
- —
- Return on equity
- 4.4%
- Return on assets
- 2.1%
- Return on capital (ROCE)
- 11.4%
- Liabilities / assets
- 51.1%
- Debt / equity
- 1.05×
- Book value / share
- $22.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- 0.5%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- 2.67safe
- Accruals / assets
- −7.6%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 good- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- LYMPHAZURINJul 29, 1981
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wehrly Peter LOfficer — Senior Vice President | Jan 26, 2015 | D | 2,317 | $0.00 |
| Tarnoff Michael EOfficer — Vice President | Jan 26, 2015 | D | 11,923 | $0.00 |
| Strayer Jacqueline FOfficer — Vice President | Jan 26, 2015 | D | 701 | $0.00 |
| Sgrignari MichaelOfficer — Senior Vice President | Jan 26, 2015 | D | 993 | $0.00 |
| Wendell Amy McbrideOfficer — Senior Vice President | Jan 26, 2015 | D | 1,887 | $0.00 |
| Masterson John HOfficer — SVP and General Counsel | Jan 26, 2015 | D | 1,738 | $0.00 |
| Lannum Coleman N IiiOfficer — Vice President | Jan 26, 2015 | D | 662 | $0.00 |
| Hanson Bryan COfficer — Senior Vice President | Jan 26, 2015 | D | 22,853 | $0.00 |
| Green Eric COfficer — Vice President | Jan 26, 2015 | D | 662 | $0.00 |
| Dunford Michael POfficer — Senior Vice President | Jan 26, 2015 | D | 1,738 | $0.00 |
| Dockendorff Charles JOfficer — EVP & Chief Financial Officer | Jan 26, 2015 | D | 3,776 | $0.00 |
| Clemmer James COfficer — Senior Vice President | Jan 26, 2015 | D | 2,152 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsFeb 3, 2015
- Director / officer changeJan 27, 2015
- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Other material eventJan 27, 2015
- Results of operationsJan 22, 2015
- Other material eventJan 12, 2015
- Shareholder vote · Other material eventJan 6, 2015
- Other material eventDec 23, 2014
- Other material eventDec 4, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from Covidien plc (1)
- Keenova Therapeutics plccompletedJun 28, 2013details
From the spin-off filings we track. Follow a company to walk its own history.